ÌÇÐÄÊÓƵ

A research group at KAIST has successfully engineered a microbial strain capable of producing lutein at industrially relevant levels. The team, led by Distinguished Professor Sang Yup Lee from the Department of Chemical and Biomolecular Engineering, developed a novel C. glutamicum strain using systems metabolic engineering strategies to overcome the limitations of previous microbial lutein production efforts.

This research is expected to be beneficial for the efficient production of other industrially important natural products used in food, pharmaceuticals, and cosmetics. The study is in the journal Nature Synthesis.

Lutein is a xanthophyll carotenoid found in egg yolk, fruits, and vegetables, known for its role in protecting our eyes from oxidative stress and reducing the risk of macular degeneration and cataracts. Currently, commercial lutein is predominantly extracted from marigold flowers; however, this approach has several drawbacks, including long cultivation times, high labor costs, and inefficient extraction yields, making it economically unfeasible for large-scale production. These challenges have driven the demand for alternative production methods.

To address these issues, KAIST researchers, including Ph.D. Candidate Hyunmin Eun, Dr. Cindy Pricilia Surya Prabowo, and Distinguished Professor Sang Yup Lee, applied systems metabolic engineering strategies to engineer C. glutamicum, a GRAS (Generally Recognized As Safe) microorganism widely used in industrial fermentation. Unlike Escherichia coli, which was previously explored for microbial lutein production, C. glutamicum lacks endotoxins, making it a safer and more viable option for food and pharmaceutical applications.

This research details the high-level production of lutein using glucose as a renewable carbon source via systems metabolic engineering. The team focused on eliminating metabolic bottlenecks that previously limited microbial lutein synthesis. By employing enzyme scaffold-based electron channeling strategies, the researchers improved metabolic flux toward lutein biosynthesis while minimizing unwanted byproducts.

To enhance productivity, bottleneck enzymes within the metabolic pathway were identified and optimized. It was determined that electron-requiring cytochrome P450 enzymes played a major role in limiting lutein biosynthesis. To overcome this limitation, an electron channeling strategy was implemented, where engineered cytochrome P450 enzymes and their reductase partners were spatially organized on synthetic scaffolds, allowing more efficient electron transfer and significantly increasing lutein production.

The engineered C. glutamicum strain was further optimized in fed-batch fermentation, achieving a record-breaking 1.78 g/L of lutein production within 54 hours, with a content of 19.51 mg/gDCW and a productivity of 32.88 mg/L/h—the highest lutein production performance in any host reported to date. This milestone demonstrates the feasibility of replacing plant-based lutein extraction with microbial fermentation technology.

"We can anticipate that this microbial cell factory-based mass production of lutein will be able to replace the current plant extraction-based process," said Ph.D. Candidate Hyunmin Eun. He emphasized that the integrated metabolic engineering strategies developed in this study could be broadly applied for the efficient production of other valuable natural products used in pharmaceuticals and nutraceuticals.

"As maintaining good health in an aging society becomes increasingly important, we expect that the technology and strategies developed here will play pivotal roles in producing other medically and nutritionally significant natural products," added Distinguished Professor Sang Yup Lee.